Mediators of Inflammation

Mediators of Inflammation / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 2061376 | 10 pages |

Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer’s Disease

Academic Editor: Hermann Gram
Received15 Nov 2017
Accepted09 Jan 2018
Published22 Feb 2018


Although there is evidence for metabolic dysfunction and chronic inflammation in Alzheimer’s disease (AD), circulating levels of soluble receptor for advanced glycation end products (sRAGE) and the receptor for advanced glycation end products (RAGE) ligand S100B have not been characterized. sRAGE is an important mediator in disease as it can act as a ligand decoy for RAGE and attenuate downstream inflammatory signaling. Cognitively healthy elderly and AD participants with and without type 2 diabetes () were stratified according to the clinical dementia rating (CDR; 0 = normal cognition (NC); ≥0.5 = AD). Total serum sRAGE, endogenous secretory RAGE (esRAGE), and S100B were assayed via ELISAs, and cleaved RAGE (cRAGE) and the cRAGE : esRAGE ratio were calculated. cRAGE : esRAGE was lower in AD compared to NC (). Metabolic substratifications were used to investigate the factors that influence sRAGE pathology in AD. Stratification by BMI classification, median fat mass, median HOMA-IR, median insulin, and median amylin were all metabolic or anthropometric factors which significantly interacted with sRAGE profiles within AD subjects. There were no significant differences in serum S100B between groups. These characterizations of sRAGE contribute evidence to the link between impaired metabolism and cognitive decline due to AD.

1. Introduction

Research has identified impaired glucose metabolism and type 2 diabetes (T2DM) as risk factors for cognitive impairment (CI) and Alzheimer’s disease (AD) [14]. Further, growing evidence of shared biochemical features between AD, T2DM, and insulin resistance (IR) suggests that AD may fundamentally be characterized as a metabolic disorder [57]. The recent increase in life expectancy has led to a greater population of individuals who are experiencing comorbid T2DM and AD, as prevalence of both T2DM and AD increases with age [8, 9]. Therefore, it is important to investigate the cellular and metabolic profiles of these individuals to give insight into the potential mechanisms underlying the onset of AD, which have yet to be fully elucidated. Recent evidence suggests that the receptor for advanced glycation end products (RAGE) may serve as an important mechanistic link [10].

RAGE is a transmembrane receptor of the immunoglobulin superfamily, thought to have evolved from a family of cell adhesion molecules [11]. RAGE has a diverse set of ligands, which include advanced glycation end products (AGEs), beta-amyloid (Aβ), and members of the S100/calgranulin protein family [12, 13]. These ligands and the RAGE protein are increased in the postmortem brains of AD patients, and interactions between RAGE and its ligands are related to the pathophysiology of chronic disease [14, 15]. More specifically, it has been documented that in the AD brain, there is an overexpression of glial-derived factors including the S100B protein [16]. At high concentrations, S100B accumulates at the surface of RAGE and activates the receptor [17]. Activation of RAGE initiates oxidative stress signaling pathways and inflammation through the transcription factor nuclear factor-kappa B (NF-κB) [18]. Chronic inflammation and excessive ROS production are hallmarks of diabetes and metabolic disorders, and increased oxidative stress in the brain is a major inducer of AD [1921]. RAGE is further implicated in the pathogenesis of AD as it plays a critical role in cerebral Aβ production and accumulation, neuronal degeneration, diminished synaptic transmission, and the formation of fibrous tangles [10]. These biological factors are considered to be the main contributors to the cognitive impairment characteristic of AD [22].

RAGE exists in two major forms: full-length, membrane bound RAGE and a circulating form termed soluble RAGE (sRAGE). Further, sRAGE is comprised of two distinct isoforms produced by unique mechanisms. Cleaved RAGE (cRAGE) is produced via proteolytic cleavage of the RAGE ectodomain by matrix metalloproteases and endogenous secretory RAGE (esRAGE) results from alternative splicing of RAGE pre-mRNA [23, 24]. Both isoforms of sRAGE lack the transmembrane and cytosolic domains necessary for signal transduction and act as a ligand decoy, thus attenuating intracellular RAGE signaling and subsequent inflammation [25]. Individuals with obesity, diabetes, or CI alone present with reduced circulating sRAGE profiles compared to lean healthy controls [2629]. This evidence has led to the emergence of sRAGE as a suggested biological marker of both glucose tolerance status [29] and cognitive decline [30, 31].

Despite the well-established link between RAGE and the pathophysiology of T2DM and AD, the effects of concurrent metabolic and cognitive derangement on sRAGE remain unknown. The purpose of this study was to investigate plasma levels of sRAGE and the RAGE ligand S100B in individuals with metabolic disturbances such as obesity, impaired fasting glucose, elevated amylin, and T2DM comorbid with AD. Our hypothesis was that individuals with concurrent metabolic derangement and AD would display decreased levels of sRAGE isoforms and elevated levels of S100B. Further, we hypothesized that plasma sRAGE levels would be inversely related to that of S100B.

2. Methods

2.1. Participants

All participants () included in this cross-sectional analysis were part of the University of Kansas Alzheimer’s Disease Center Clinical Cohort and provided written informed consent according to the University of Kansas Medical Center’s institutional guidelines. Eligible participants were postmenopausal, on stable medicine, and able to provide informed consent. Exclusion criteria included diagnosis of type 1 diabetes, clinically significant depression, or any neurodegenerative disorders other than AD. We a priori included samples from an approximately equal number of T2DM participants in both the ND and AD groups.

2.2. Clinical Characterization and Measurements

Individuals were clinically assessed, and dementia severity was characterized using the Clinical Dementia Rating (CDR). All subjects underwent neuropsychometric testing. Diagnosis was confirmed at a consensus diagnosis conference based on clinical information and neuropsychometric performance. Participants were considered to have normal cognition (NC) if they were CDR 0 with no clinically significant deficits on cognitive testing. All AD subjects were diagnosed as either mild cognitive impairment due to probable AD or dementia due to probable AD at the time of the blood draw. All AD subjects had a CDR of 0.5 or higher.

For characterization by apolipoprotein ε4 (APOE4) genotype, DNA was isolated from whole blood and sent to the National Cell Repository for Alzheimer’s Disease (NCRAD) for genotyping. Participants were classified as either APOE4 carriers or noncarriers based on the presence of a single APOE4 allele.

American Diabetes Association (ADA) criteria were used to characterize the fasting glucose status (FGS) of participants. Participants were categorized as having normal fasting glucose (NFG, <100 mg/dL), impaired fasting glucose (IFG, 100–125 mg/dL), or diabetes (T2DM, >125 mg/dL). Further, homeostatic model assessment of insulin resistance (HOMA-IR) was computed as a measure of insulin sensitivity [32].

World Health Organization (WHO) criteria were used to characterize the body mass index (BMI) of participants. Participants were classified as lean (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), or obese (>30 kg/m2). Body composition was assessed via dual-energy X-ray absorptiometry (DEXA, Lunar Prodigy, version 11.2068) for measures of lean body mass and fat mass.

2.3. Serum Analysis

Participants reported to the clinic following an overnight fast, and blood was collected via venipuncture into serum vacutainer tubes containing clot activator. Blood was processed for serum, and glucose was measured using a YSI 2300 Stat Plus Glucose Lactate Analyzer. All remaining serum was stored at −80°C until further analysis. Insulin (Genway), amylin (Millipore), S100B (Millipore), sRAGE (R&D), and esRAGE (As One International) were quantified using ELISA per the manufacturer’s protocol. Serum cRAGE was computed by subtracting esRAGE from the total plasma sRAGE pool as previously described [33], and the cRAGE : esRAGE ratio was subsequently calculated [29].

2.4. Statistics

All data were tested for normality using Shapiro-Wilk’s test. Nonnormally distributed data was log-transformed and retested for normality. The Student’s t-test was used to compare serum sRAGE and S100B profiles between the AD and NC groups. An analysis of variance (ANOVA) and Bonferroni post hoc analysis were used to determine significant differences in sRAGE isoforms between cognition groups and across important metabolic factors. An analysis of covariance (ANCOVA) was used following the ANOVA to determine the effects of age and sex, two well-established influences in AD pathology. Pearson’s correlation coefficient was used to determine bivariate correlation analyses. All data are presented as mean ± SEM, and differences were determined statistically significant at a value < 0.05.

3. Results

3.1. Subject Characteristics

Cognition groups were weighted equally with T2DM participants. There were no significant differences between cognition groups with respect to fasting glucose, fasting insulin, or HOMA-IR (Table 1). There was also no difference in age or lean body mass between groups; however, the AD group did have a significantly lower BMI () and fat mass () compared to the NC group (Table 1).

Variable (units)NC ()AD ()

Sex (number, % males)26, 38%36, 54%
Age (y)73 ± 175 ± 1
BMI (kg/m2)29.5 ± 0.527.3 ± 0.8
Lean body mass (kg)46 ± 146 ± 1
Fat mass (kg)32 ± 127 ± 1
Type 2 diabetes (number, %)22, 32%19, 28%
HOMA-IR (AU)2.4 ± 0.32.2 ± 0.2
Fasting glucose (mg/dL)104 ± 3101 ± 2
Fasting glucose (mmol/L)5.8 ± 0.25.6 ± 0.1
Fasting insulin (mU/L)9.1 ± 1.08.8 ± 0.8
Fasting amylin (pM)11.2 ± 1.717.9 ± 5.3
S100B (pg/mL)13.0 ± 1.714.4 ± 2.8

Data are presented as mean ± SEM. BMI: body mass index; HOMA-IR: homeostatic model assessment of insulin resistance. .
3.2. The Effect of Alzheimer’s Disease on sRAGE Isoforms

There were no significant differences in total serum sRAGE between the AD and NC groups; however, individuals with AD had a significantly reduced cRAGE : esRAGE ratio () compared to those with NC (Figures 1(a) and 1(d)). Although the cRAGE and esRAGE isoforms alone were not significantly different between groups ( and 0.79, resp.), trending suggests that the 14.4% attenuation in the ratio is likely due to a preferential loss in cRAGE rather than esRAGE (Figures 1(b) and 1(c)).

3.3. The Effect of AD, Age, and APOE4 Genotype on sRAGE Isoforms

Given the altered sRAGE profile with AD presented in Figure 1, we aimed to identify any effects that age or genotype may have on serum sRAGE isoforms. First, stratification by decade of age (60–69, 70–79, 80–89 y) revealed a main effect of AD on cRAGE () but no significant differences between groups for total sRAGE, esRAGE, or the cRAGE : esRAGE ratio. We next stratified by APOE4 genotype, the primary risk gene in AD [34], and found significant main effects of AD on total sRAGE, cRAGE, and the cRAGE : esRAGE ratio (, 0.02, and 0.01). There were no main effects of age or genotype nor any interactions between the above factors and AD status on any of the sRAGE variables. These findings suggest that age and APOE4 genotype may be important factors in the diminished cRAGE with AD.

3.4. The Effect of AD and Metabolic Dysfunction on sRAGE Isoforms

To better characterize the effects of metabolic factors on sRAGE pathophysiology in AD, all participants were stratified by the following factors: T2DM diagnosis, FGS as determined by ADA criteria, obesity by BMI according to the WHO, median insulin, median amylin, median HOMA-IR, and median fat mass. The above factors were selected for investigation due to their independent importance in disease pathophysiology and sRAGE biology. For example, we have previously found that glucose tolerance and obesity have a strong influence on sRAGE [29] and that adiposity (fat mass) is associated with attenuated sRAGE pools [35]. Further, this project aimed to characterize sRAGE profiles by cognitive status and commonly used markers of metabolic health to serve as a foundation for future work.

Total serum sRAGE and esRAGE were not significantly different between individuals with or without T2DM comorbid with AD. However, there was a significant main effect of AD on serum cRAGE and the cRAGE : esRAGE ratio (, 0.03), showing decreased levels of these sRAGE isoforms with AD (data not shown). Similarly, when stratified by FGS, there was a main effect of AD, which highlighted lower total sRAGE and cRAGE compared to NC counterparts (, 0.02; data not shown).

Obesity stratification by BMI revealed main effects of AD on total sRAGE, cRAGE, and cRAGE : esRAGE ratio (, <0.01, and 0.02), main effects of obesity status on total sRAGE and cRAGE (, 0.01), and interaction effects on total sRAGE, esRAGE, and cRAGE (, 0.02, and 0.02). Post hoc analysis showed that within the NC group, those who are overweight have significantly lower total sRAGE, cRAGE, and esRAGE than their lean counterparts (, 0.02, and 0.02; Figure 2). Similarly, within the AD group, obese individuals have significantly reduced cRAGE compared to lean individuals (; Figure 2(b)). Those with comorbid obesity and AD have significantly lower total sRAGE and cRAGE compared to obese NC individuals (, <0.01; Figure 2). When stratified by median fat mass (28.95 kg), the AD group had lower serum cRAGE and cRAGE : esRAGE (, 0.02; Figure 3). Interaction effects between AD status and fat mass highlighted significant attenuation of total sRAGE, cRAGE, and the cRAGE : esRAGE ratio with AD compared to NC in the high fat mass group (, <0.01, and <0.01; Figure 3). As shown in Figure 3, individuals in the AD group with high fat mass had 4.1% less cRAGE and a 21.2% reduction in the cRAGE : esRAGE ratio compared to their counterparts with low fat mass (, 0.02).

HOMA-IR was calculated as an indicator of insulin resistance, and participants were stratified by the calculated median (1.66 AU). This data showed a significant difference between the AD and NC groups in serum cRAGE and the cRAGE : esRAGE ratio (, 0.02; Figure 4). Additionally, within the high HOMA-IR group, individuals with concurrent AD had a 25.7% lower cRAGE : esRAGE ratio (; Figure 4). Fasting HOMA-IR was also negatively correlated to log-transformed serum cRAGE (, ).

Insulin and amylin were found to have a similar influence on serum sRAGE profiles in AD, but amylin was of special interest due to its ability to colocalize with Aβ plaques in AD [36]. Outlined in Figures 5 and 6, when stratified by median insulin (6.83 mU/L) and median amylin (6.75 pM), individuals with AD presented with lower cRAGE (, 0.03) and cRAGE : esRAGE (, 0.01). In addition, there was an interaction between AD and both insulin group and amylin group (, <0.01; Figures 5 and 6). Within both the high insulin and high amylin groups, those with concurrent AD displayed aberrant serum cRAGE : esRAGE ratios compared to NC counterparts, with a 25.6% and 30.1% attenuation, respectively (, <0.01). Related, fasting amylin was negatively correlated to log-transformed values of both the esRAGE (, ) and the cRAGE isoforms (, ). Fasting insulin was also negatively correlated to log-transformed serum cRAGE (, ).

To understand any influence that the well-established factors of age and sex may have on AD-related outcomes, we ran ANCOVAs for these factors. All of the significant interactions we found between the experimental metabolic factors of interest and AD status on sRAGE profiles were maintained with covariance for age and sex (data not shown).

3.5. The Effect of AD on the sRAGE Ligand S100B

There were no significant differences in serum S100B between the AD and NC groups (Table 1). Ratios between serum S100B and serum total sRAGE, esRAGE, and cRAGE were generated to investigate RAGE ligand and sRAGE dynamics. Analyses showed no significant differences across AD diagnosis (data not shown). Additionally, there were no significant correlations among S100B, total sRAGE, or any of the sRAGE isoforms. We further investigated serum S100B against determinants of metabolic health (fat mass, BMI, insulin, glucose, and HOMA-IR) and found no significant relationships.

4. Discussion

To our knowledge, this is the first report to characterize total sRAGE and all sRAGE isoforms in individuals with and without Alzheimer’s disease and comorbid T2DM. Our data show that individuals with metabolic derangement (elevated insulin, amylin, HOMA-IR, BMI, or fat mass) concurrent with AD present with aberrant sRAGE profiles. These findings are in line with other published work that shows decreased plasma sRAGE in individuals with cognitive impairment, obesity, and IR [26, 30, 37] and further supports the protective role of sRAGE in inflammatory diseases.

Novel findings of importance were the alterations in the sRAGE profile when individuals were stratified by AD diagnosis and median amylin. Fasting amylin was also negatively correlated to both esRAGE and cRAGE. Amylin readily crosses the blood-brain barrier and is known to play an important role in mediating brain function [38]. Further, amylin and Aβ share many chemical features, as both molecules bind to the same amylin-3 receptor in the brain [39]. Under pathological conditions, amylin can form insoluble amylin amyloid plaques, which have been found to colocalize with Aβ plaques in AD [36]. Abnormal amylin is central to T2DM progression as it is seen in both early stages (elevated amylin) and late stages (suppressed amylin) of the disease [40]. This, combined with the known relationship between RAGE and neurodegenerative disorders, highlights the link between abnormal amylin, depressed sRAGE, and Alzheimer’s disease seen in our results.

We also showed that when our analyses were covaried for both age and sex, all interaction effects between metabolic dysfunction and AD status remained significant. Similarly, when individuals were stratified by decade of age or APOE4 genotype, there were neither any main effects of these variables nor an interaction with AD status. Although APOE4 genotype and increasing age are well-established risk factors for late-onset AD, previous studies have found that total plasma sRAGE levels are able to predict cognitive decline seen in late-onset AD [30]. Together with our data, these findings suggest that widespread metabolic dysfunction, rather than more traditional risk factors, may be more important drivers of AD in some individuals.

However, when we examined sRAGE in individuals with AD, T2DM status did not impact total sRAGE or any specific isoforms. This differs from previous work out of our lab and others that suggest diminished sRAGE pools in individuals with T2DM compared to healthy controls [29, 41]. There is also conflicting evidence demonstrating that increased total sRAGE is associated with diabetes [42]. One possible explanation for this difference may be that in the present, all study participants remained on their T2DM medication, whereas Basta et al. only included T2DM subjects without medication [41]. Another possible explanation is that many of these volunteers may be newly diagnosed with T2DM or have adequate glycemic control as the median HOMA-IR of our T2DM participants was 2.45, much lower than previous established cutoffs [43]. Lastly, it may be possible that AD pathology may present similarly to T2DM and thus may mask any unique effects of T2DM on sRAGE isoforms.

S100B is thought to mediate neuroinflammation and contribute to both AD pathogenesis and systemic inflammation seen in metabolic disease. Importantly, S100B is overexpressed in the brain of AD patients [44, 45] and elevated in serum of persons with obesity [46]. However, reports of S100B in cerebral spinal fluid (CSF) and serum of AD patients are conflicting. Peskind et al. reported elevated CSF S100B in individuals with mild to moderate AD compared to controls [47], while Nooijen et al. found no difference in CSF S100B with dementia [48]. Chaves et al. reported lower serum S100B in AD compared to controls [49], which differs with our cross-sectional analysis, as we did not see any differences in serum S100B across AD status. A possible explanation of our findings is that elevated RAGE in the AD brain sequesters and traps S100B proteins in brain tissue, preventing it from appearing in the serum despite the compromised blood-brain barrier in AD. Similar RAGE trapping mechanisms have been previously reported in adipose tissue for advanced glycated end products [50]. Further, adipose tissue serves as a site of S100B protein concentration comparable to neuronal tissue [51, 52]. S100B secretion from adipocytes is related to lipolysis [53], inhibited by insulin [54], and thus is subject to dysregulation by diabetes and other metabolic diseases. This may further explain our findings as we balanced the number of T2DM participants across cognitive groups. These data further illuminate the need to consider metabolic covariates when assessing neurocognitive disorders. Postmortem analysis of brain sections combined with CSF and serum analyses may help to clarify the role and origin of S100B in the pathogenesis of AD.

In conclusion, the following metabolic factors have been shown to influence total sRAGE and individual sRAGE isoforms in Alzheimer’s disease: elevated insulin, amylin, insulin resistance as described by HOMA-IR, obesity by BMI, and high fat mass. It is possible that the attenuated plasma sRAGE seen in individuals with metabolic dysfunction may be contributing to AD due to a reduced capacity to scavenge RAGE ligands and attenuate RAGE signaling. Activation of RAGE produces oxidative stress and inflammation in the brain, neuronal degeneration, and Aβ accumulation, all inducers of cognitive impairment and AD [10, 20]. These novel characterizations of sRAGE in individuals with concurrent metabolic derangement and AD contribute evidence to the link between impaired metabolism and cognitive decline.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.


This work was supported by the National Institutes of Health [R01 DK109948 (Jacob M. Haus), K99 AG050490 (Jill K. Morris), and P30AG035982 Jill K. Morris)].


  1. J. A. Luchsinger and D. R. Gustafson, “Adiposity, type 2 diabetes, and Alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 16, no. 4, pp. 693–704, 2009. View at: Publisher Site | Google Scholar
  2. J. A. Luchsinger, M.-X. Tang, S. Shea, and R. Mayeux, “Hyperinsulinemia and risk of Alzheimer disease,” Neurology, vol. 63, no. 7, pp. 1187–1192, 2004. View at: Publisher Site | Google Scholar
  3. S. Hoyer, “Glucose metabolism and insulin receptor signal transduction in Alzheimer disease,” European Journal of Pharmacology, vol. 490, no. 1-3, pp. 115–125, 2004. View at: Publisher Site | Google Scholar
  4. A. M. Rawlings, A. R. Sharrett, T. H. Mosley, S. H. Ballew, J. A. Deal, and E. Selvin, “Glucose peaks and the risk of dementia and 20-year cognitive decline,” Diabetes Care, vol. 40, no. 7, pp. 879–886, 2017. View at: Publisher Site | Google Scholar
  5. S. M. de la Monte and M. Tong, “Brain metabolic dysfunction at the core of Alzheimer’s disease,” Biochemical Pharmacology, vol. 88, no. 4, pp. 548–559, 2014. View at: Publisher Site | Google Scholar
  6. Z. Chen and C. Zhong, “Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies,” Progress in Neurobiology, vol. 108, pp. 21–43, 2013. View at: Publisher Site | Google Scholar
  7. S. Craft, “The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged?” Archives of Neurology, vol. 66, no. 3, pp. 300–305, 2009. View at: Publisher Site | Google Scholar
  8. R. I. Fink, O. G. Kolterman, J. Griffin, and J. M. Olefsky, “Mechanisms of insulin resistance in aging,” Journal of Clinical Investigation, vol. 71, no. 6, pp. 1523–1535, 1983. View at: Publisher Site | Google Scholar
  9. W. A. Rocca, A. Hofman, C. Brayne et al., “Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings,” Annals of Neurology, vol. 30, no. 3, pp. 381–390, 1991. View at: Publisher Site | Google Scholar
  10. Z. Cai, N. Liu, C. Wang et al., “Role of RAGE in Alzheimer’s disease,” Cellular and Molecular Neurobiology, vol. 36, no. 4, pp. 483–495, 2016. View at: Publisher Site | Google Scholar
  11. L. Sessa, E. Gatti, F. Zeni et al., “The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs),” PLoS One, vol. 9, no. 1, article e86903, 2014. View at: Publisher Site | Google Scholar
  12. M. Neeper, A. M. Schmidt, J. Brett et al., “Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins,” Journal of Biological Chemistry, vol. 267, no. 21, pp. 14998–15004, 1992. View at: Google Scholar
  13. L. J. Sparvero, D. Asafu-Adjei, R. Kang et al., “RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation,” Journal of Translational Medicine, vol. 7, no. 1, p. 17, 2009. View at: Publisher Site | Google Scholar
  14. N. Taniguchi, M. Takahashi, Y. Kizuka et al., “Glycation vs. glycosylation: a tale of two different chemistries and biology in Alzheimer’s disease,” Glycoconjugate Journal, vol. 33, no. 4, pp. 487–497, 2016. View at: Publisher Site | Google Scholar
  15. M. C. Miller, R. Tavares, C. E. Johanson et al., “Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease,” Brain Research, vol. 1230, pp. 273–280, 2008. View at: Publisher Site | Google Scholar
  16. R. E. Mrak and W. S. Griffinbc, “The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 915–922, 2001. View at: Publisher Site | Google Scholar
  17. C. Cirillo, E. Capoccia, T. Iuvone et al., “S100B inhibitor pentamidine attenuates reactive gliosis and reduces neuronal loss in a mouse model of Alzheimer’s disease,” BioMed Research International, vol. 2015, Article ID 508342, 11 pages, 2015. View at: Publisher Site | Google Scholar
  18. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001. View at: Publisher Site | Google Scholar
  19. V. P. Singh, A. Bali, N. Singh, and A. S. Jaggi, “Advanced glycation end products and diabetic complications,” The Korean Journal of Physiology & Pharmacology, vol. 18, no. 1, pp. 1–14, 2014. View at: Publisher Site | Google Scholar
  20. G. Perry, A. D. Cash, and M. A. Smith, “Alzheimer disease and oxidative stress,” Journal of Biomedicine and Biotechnology, vol. 2, no. 3, pp. 120–123, 2002. View at: Publisher Site | Google Scholar
  21. E. Kosenko, G. Aliev, L. Tikhonova, Y. Li, A. Poghosyan, and Y. Kaminsky, “Antioxidant status and energy state of erythrocytes in Alzheimer dementia: probing for markers,” CNS & Neurological Disorders - Drug Targets, vol. 11, no. 7, pp. 926–932, 2012. View at: Publisher Site | Google Scholar
  22. J. Pozueta, R. Lefort, and M. L. Shelanski, “Synaptic changes in Alzheimer’s disease and its models,” Neuroscience, vol. 251, pp. 51–65, 2013. View at: Publisher Site | Google Scholar
  23. A. Raucci, S. Cugusi, A. Antonelli et al., “A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10),” The FASEB Journal, vol. 22, no. 10, pp. 3716–3727, 2008. View at: Publisher Site | Google Scholar
  24. H. Yonekura, Y. Yamamoto, S. Sakurai et al., “Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury,” Biochemical Journal, vol. 370, no. 3, pp. 1097–1109, 2003. View at: Publisher Site | Google Scholar
  25. S. Zeng, N. Feirt, M. Goldstein et al., “Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice,” Hepatology, vol. 39, no. 2, pp. 422–432, 2004. View at: Publisher Site | Google Scholar
  26. E. Dozio, S. Briganti, A. Delnevo et al., “Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women,” European Journal of Nutrition, vol. 56, no. 8, pp. 2557–2564, 2017. View at: Publisher Site | Google Scholar
  27. T. M. Motawi, M. A. Abou-Seif, A. M. Bader, and M. O. Mahmoud, “Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients,” BMC Endocrine Disorders, vol. 13, no. 1, 2013. View at: Publisher Site | Google Scholar
  28. E. Emanuele, A. D’Angelo, C. Tomaino et al., “Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia,” Archives of Neurology, vol. 62, no. 11, pp. 1734–1736, 2005. View at: Publisher Site | Google Scholar
  29. E. R. Miranda, V. S. Somal, J. T. Mey et al., “Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes,” American Journal of Physiology-Endocrinology and Metabolism, vol. 313, no. 6, pp. E631–E640, 2017. View at: Publisher Site | Google Scholar
  30. R. Ghidoni, L. Benussi, M. Glionna et al., “Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment,” Journal of Neural Transmission, vol. 115, no. 7, pp. 1047–1050, 2008. View at: Publisher Site | Google Scholar
  31. X. Y. Xu, C. Q. Deng, J. Wang et al., “Plasma levels of soluble receptor for advanced glycation end products in Alzheimer’s disease,” International Journal of Neuroscience, vol. 127, no. 5, pp. 454–458, 2017. View at: Publisher Site | Google Scholar
  32. B. Singh and A. Saxena, “Surrogate markers of insulin resistance: a review,” World Journal of Diabetes, vol. 1, no. 2, pp. 36–47, 2010. View at: Publisher Site | Google Scholar
  33. S. C. Tang, S. J. Yeh, L. K. Tsai et al., “Cleaved but not endogenous secretory RAGE is associated with outcome in acute ischemic stroke,” Neurology, vol. 86, no. 3, pp. 270–276, 2016. View at: Publisher Site | Google Scholar
  34. E. M. Reiman, K. Chen, X. Liu et al., “Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 16, pp. 6820–6825, 2009. View at: Publisher Site | Google Scholar
  35. E. Miranda, K. Varady, and J. Haus, “Weight loss via alternate day fasting increases circulating endogenous secretory RAGE and is associated with markers of adipocyte health,” The FASEB Journal, vol. 31, p. 3, 2017. View at: Google Scholar
  36. K. Jackson, G. A. Barisone, E. Diaz, L. W. Jin, C. DeCarli, and F. Despa, “Amylin deposition in the brain: a second amyloid in Alzheimer disease?” Annals of Neurology, vol. 74, no. 4, pp. 517–526, 2013. View at: Publisher Site | Google Scholar
  37. I. Hagen, D. M. Schulte, N. Müller et al., “Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects,” Cytokine, vol. 73, no. 2, pp. 265–269, 2015. View at: Publisher Site | Google Scholar
  38. W. Q. Qiu, H. Li, H. Zhu et al., “Plasma amylin and cognition in diabetes in the absence and the presence of insulin treatment,” Journal of Diabetes & Metabolism, vol. 5, no. 11, 2014. View at: Publisher Site | Google Scholar
  39. W. Fu, A. Ruangkittisakul, D. MacTavish, J. Y. Shi, K. Ballanyi, and J. H. Jhamandas, “Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways,” Journal of Biological Chemistry, vol. 287, no. 22, pp. 18820–18830, 2012. View at: Publisher Site | Google Scholar
  40. T. A. Lutz and U. Meyer, “Amylin at the interface between metabolic and neurodegenerative disorders,” Frontiers in Neuroscience, vol. 9, no. 216, 2015. View at: Publisher Site | Google Scholar
  41. G. Basta, A. M. Sironi, G. Lazzerini et al., “Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 11, pp. 4628–4634, 2006. View at: Publisher Site | Google Scholar
  42. K. C. B. Tan, S. W. M. Shiu, W. S. Chow, L. Leng, R. Bucala, and D. J. Betteridge, “Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes,” Diabetologia, vol. 49, no. 11, pp. 2756–2762, 2006. View at: Publisher Site | Google Scholar
  43. S. E. Stern, K. Williams, E. Ferrannini, R. A. DeFronzo, C. Bogardus, and M. P. Stern, “Identification of individuals with insulin resistance using routine clinical measurements,” Diabetes, vol. 54, no. 2, pp. 333–339, 2005. View at: Publisher Site | Google Scholar
  44. E. Leclerc, E. Sturchler, and S. W. Vetter, “The S100B/RAGE axis in Alzheimer’s disease,” Cardiovascular Psychiatry and Neurology, vol. 2010, Article ID 539581, 11 pages, 2010. View at: Publisher Site | Google Scholar
  45. F. Michetti, V. Corvino, M. C. Geloso et al., “The S100B protein in biological fluids: more than a lifelong biomarker of brain distress,” Journal of Neurochemistry, vol. 120, no. 5, pp. 644–659, 2012. View at: Publisher Site | Google Scholar
  46. J. Steiner, K. Schiltz, M. Walter et al., “S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research,” Psychoneuroendocrinology, vol. 35, no. 2, pp. 321–324, 2010. View at: Publisher Site | Google Scholar
  47. E. R. Peskind, W. S. Griffin, K. T. Akama, M. A. Raskind, and L. J. Van Eldik, “Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease,” Neurochemistry International, vol. 39, no. 5-6, pp. 409–413, 2001. View at: Publisher Site | Google Scholar
  48. P. T. Nooijen, H. C. Schoonderwaldt, R. A. Wevers, O. R. Hommes, and K. J. Lamers, “Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia,” Dementia and Geriatric Cognitive Disorders, vol. 8, no. 3, pp. 169–173, 1997. View at: Publisher Site | Google Scholar
  49. M. L. Chaves, A. L. Camozzato, E. D. Ferreira et al., “Serum levels of S100B and NSE proteins in Alzheimer’s disease patients,” Journal of Neuroinflammation, vol. 7, no. 1, p. 6, 2010. View at: Publisher Site | Google Scholar
  50. K. H. J. Gaens, G. H. Goossens, P. M. Niessen et al., “Nε-(Carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 6, pp. 1199–1208, 2014. View at: Publisher Site | Google Scholar
  51. H. Hidaka, T. Endo, S. Kawamoto et al., “Purification and characterization of adipose tissue S-100b protein,” Journal of Biological Chemistry, vol. 258, no. 4, pp. 2705–2709, 1983. View at: Google Scholar
  52. F. Michetti, E. Dell'Anna, G. Tiberio, and D. Cocchia, “Immunochemical and immunocytochemical study of S-100 protein in rat adipocytes,” Brain Research, vol. 262, no. 2, pp. 352–356, 1983. View at: Publisher Site | Google Scholar
  53. C. B. Netto, S. Conte, M. C. Leite et al., “Serum S100B protein is increased in fasting rats,” Archives of Medical Research, vol. 37, no. 5, pp. 683–686, 2006. View at: Publisher Site | Google Scholar
  54. F. Suzuki and K. Kato, “Inhibition of adipose S-100 protein release by insulin,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 845, no. 2, pp. 311–316, 1985. View at: Publisher Site | Google Scholar

Copyright © 2018 Kelly N. Z. Fuller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

773 Views | 261 Downloads | 7 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.